Moderna, Inc. - Common Stock (MRNA)

Sandisk is changing its business model to reduce its cyclicality.

Momentum is only half the battle. Their underlying companies still need to justify the continued bullishness of their stocks.

What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r...

This stock has soared more than 600% this year.

Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.

Is bigger always better? Not necessarily.

Forget the "Magnificent Seven" in favor of the "Tremendous Three"?

After a few years of stagnation, this stock is soaring.

The biotech could play a significant role in a national effort to combat cancer.

Have Moderna’s shares risen too much, too fast?

Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.

These stocks have all soared more than 350% this year.